Does RNAZ pay a dividend and is it safe?

TransCode Therapeutics Inc. (RNAZ) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Stock Ratings / Health Care / RNAZ / dividends

CPHI (35) RMTI (23) ABVC (32) BCTX (40) ⌘ Pro Terminal →

TransCode Therapeutics Inc. (RNAZ) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.63 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.63

TransCode Therapeutics Inc. (RNAZ) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $27.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RNAZ Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RNAZ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, TransCode Therapeutics Inc. (NASDAQ: RNAZ) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $1.63 (0.00% 1D, market cap $27.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 9/20, and Executive Insider Alignment 5/20. Across 1015 tracked Health Care issuers, RNAZ ranks #605 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RNAZ compare to CPHI and RMTI in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RNAZ carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CPHI (China Pharma Holdings Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -11.4%, cap $26.9M) and RMTI (Rockwell Medical Inc.) posts a E grade (23/100 RQD, P/E N/A, ROIC -10.6%, cap $28.5M). Among the 5-stock peer group, RNAZ leads on earnings multiple (N/A) while RMTI leads on capital efficiency (-10.6% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RNAZ?

▼

Per RNAZ's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001829635), TransCode Therapeutics Inc. generated $78.3M in revenue (+78.7% YoY), -$34.7M in net income, and -$19.5M in free cash flow against $162.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.63 (-0.19%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (35/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-8.5% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 Quant Analysts Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-10.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RNAZ)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (35/100 Composite)

🔍 WHY RNAZ SCORES 35/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (26% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 42.2 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$1.68+0% Next Q

Q2 (-2Q)

Grade D$1.68-0.6% Next Q

Q3 (-1Q)

Grade E$1.67-2.4% Next Q

Current

Grade D-$1.63-8.5% Hist 90D α

Trajectory: D (43) → D- (35)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a RNAZ Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While RNAZ currently carries a cautious 35/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.79) and Max Pain ($1.71) forces dealer call-delta covering toward $13.23.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RNAZ• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “RNAZ Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 35%NO 65%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

1.8% Total Yield

0% Cash ($0.00/yr) + 1.8% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.7K

Yr 1

$11.4K

Yr 2

$12.2K

Yr 3

$13.0K

Yr 4

$13.9K

Yr 5

$14.8K

Yr 6

$15.8K

Yr 7

$16.9K

Yr 8

$18.1K

Yr 9

$19.3K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring RNAZ)

✓Walkthrough of RNAZ's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

RNAZ // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -78.94%⚡ TESTING RESISTANCE

2026-11-03O $1.73H $1.73L $1.63C $1.63VOL 16.2K

RES: $1.75SUP: $0.52SMA50: $1.79SMA200: $6.08

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RNAZ Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RNAZ Butterfly Map → + Track RNAZ →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +78.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on RNAZ today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RNAZ. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for RNAZ today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RNAZ)

Health Care Rank #605 of 1015 ⚔️ CPHI vs RNAZ Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RNAZ vs. CPHI, RMTI, ABVC, BCTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, TransCode Therapeutics Inc. (RNAZ) ranks #605 by composite RQD confidence (35/100, grade D-) and #807 by equity capitalization ($27.6M). Within this direct 5-issuer industry benchmark cohort, RNAZ leads on earnings valuation at N/A trailing P/E, while RMTI leads on capital efficiency and profitability with -10.6% ROIC and 16.9% gross margin. BCTX currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with RNAZ at 35/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
RNAZ ACTIVE TransCode Therapeutics Inc.	D-	35/100	—	—	-35.0%	0.00%	$27.6M	Benchmark Subject
CPHI China Pharma Holdings Inc.	D-	35/100	—	-3.2%	-11.4%	-2.98%	$26.9M	/cphi-vs-rnaz →
RMTI Rockwell Medical Inc.	E	23/100	—	16.9%	-10.6%	-2.26%	$28.5M	/rmti-vs-rnaz →
ABVC ABVC BioPharma Inc.	E	32/100	—	—	-35.0%	-1.99%	$26.7M	/abvc-vs-rnaz →
BCTX BriaCell Therapeutics Corp.	D-	40/100	—	—	—	+1.65%	$26.5M	/bctx-vs-rnaz →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001829635 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), TransCode Therapeutics Inc. (RNAZ) reported GAAP revenue of $78.3M (+78.7% vs. FY2024 revenue of $43.8M , and +44.1% cumulative change since FY2023) , GAAP net income of -$34.7M, operating cash flow of -$19.5M, and free cash flow of -$19.5M (-46.2% YoY). On the balance sheet, RNAZ closed FY2025 with $162.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$78.3M	-$34.7M	-$19.5M	-$19.5M	$162.4M	—
FY2024 (FY)	2024-12-31	$43.8M	-$16.8M	-$13.3M	-$13.4M	$7.3M	—
FY2023 (FY)	2023-12-31	$54.4M	-$18.5M	-$18.1M	-$18.1M	—	—

3. RNAZ Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RNAZ stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does RNAZ compare to CPHI and RMTI in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for RNAZ?

Where is RNAZ trading relative to its 50-day, 200-day, and 52-week technical levels?

RNAZ last traded at $1.63 (0.00% on volume of 16,525 shares), positioning the stock -8.94% below its 50-day simple moving average ($1.79) and -73.19% below its 200-day simple moving average ($6.08). Across its 52-week range of $1.52 to $12.60, RNAZ sits at the 1.0% percentile with a 14-day RSI of 42.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.43 to $1.83).

Direct Sub-Reports: RNAZ RQD Cockpit RNAZ 12M Forecast RNAZ Earnings & Move RNAZ Dividends & DRIP RNAZ Insiders & 13F RNAZ Whale Options RNAZ Profit Sankey RNAZ News & Why

ROARABLE RATING BRIEF • RQD 35/100 (D-) ✓ SEC XBRL & RQD VERIFIED

RNAZ — TransCode Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

TransCode Therapeutics Inc. (RNAZ) earns a live Roarable RQD composite score of 35/100, corresponding to a D- letter grade (Roarable Sell) at a spot price of $1.63 (0.00% 1D, market capitalization $27.6M).

Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of —.
Whale 13F & Options Flow (3/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (9/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

TransCode Therapeutics Inc. Is a NASDAQ-listed company in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry..0B. Reported revenue is — across the periods provided, indicating no revenue has been recognized in those periods.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), TransCode Therapeutics Inc. (RNAZ) reported $78.3M in annual revenue (up from $43.8M in FY2024, +78.7% YoY) and -$34.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($54.4M revenue, -$18.5M net income) through FY2025, RNAZ scaled operating cash flow to -$19.5M and free cash flow to -$19.5M, backed by $162.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (D- • RQD 35/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.52 – $12.60 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies: — Sector correlations beyond the stated beta of 1.0: — A prospective investor should watch whether the strategic-options process described in the news wire produces a licensing or sale transaction, as that would be a second-order event not captured in the graph.

Key Question #1: Can RNAZ sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $78.3M and free cash flow of -$19.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is RNAZ's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

RNAZ Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for TransCode Therapeutics Inc. (RNAZ) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RNAZ Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 1d ago

TransCode Therapeutics Presents Phase 1a Clinical Data for TTX-MC138 at ESMO Congress 2026

Yahoo Finance report covering TransCode Therapeutics Inc. (RNAZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE www.marketscreener.com • 1d ago

TransCode Therapeutics, Inc. Engages Tungsten Advisors to Consider Strategic Options

www.marketscreener.com report covering TransCode Therapeutics Inc. (RNAZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

An experimental cancer treatment could be licensed or sold as TransCode weighs options

Stock Titan report covering TransCode Therapeutics Inc. (RNAZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Syfe • 1d ago

RNAZ Stock Price, Quote & News

Syfe report covering TransCode Therapeutics Inc. (RNAZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

TransCode Therapeutics, Inc. (RNAZ) Seasonal Returns Chart - Yahoo Finance

Yahoo! Finance Canada report covering TransCode Therapeutics Inc. (RNAZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE www.marketscreener.com • 1d ago

Transcode Therapeutics, Inc. Presents Phase 1A Clinical Trial Data for Ttx-Mc138 At Esmo Congress 2026

www.marketscreener.com report covering TransCode Therapeutics Inc. (RNAZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Stock Titan • 2d ago

The cancer treatment showed exploratory signs of immune activity against tumors.

Stock Titan report covering TransCode Therapeutics Inc. (RNAZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 2d ago

Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer

Yahoo Finance report covering TransCode Therapeutics Inc. (RNAZ) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RNAZ Bull vs. Bear Conversation Board — What's Your Call at $1.63?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RNAZ 🐻 33% BEARISH CONVICTION

TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $1.96 (+20.2%)

📌 Pinned Debate

The company is reportedly pursuing strategic options and presented Phase 1a clinical data for TTX-MC138, which could create value from

Long RNAZ at $1.63 targeting $1.96. The company is reportedly pursuing strategic options and presented Phase 1a clinical data for TTX-MC138, which could create value from its pipeline.. Institutional whale score is 3/20 and the risk/reward vs. the $1.52 52-week low is skewed heavily in favor of bulls.

SectorRotator 🐂 BULL

@TapeReader_Pro Agree on the RQD 35/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.63 and keeping dry powder in case we test $1.52.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $1.29 (-20.9%)

Spot @ $1.63

With FY 2025 free cash flow of -$19.5M against $17.8M of cash, a Piotroski F-Score of 2/9, and ROIC of -35%, the balance sheet and cash

Sitting on the sidelines or leaning short RNAZ above $1.63. With FY 2025 free cash flow of -$19.5M against $17.8M of cash, a Piotroski F-Score of 2/9, and ROIC of -35%, the balance sheet and cash engine score weakly.. Until Fundamental Cash Engine (8/20) and FCF yield (0.0%) inflect higher, upside is capped near $12.60.